

# **Severe Acute Respiratory Syndrome (SARS) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs**

<https://marketpublishers.com/r/SD0B0A15E345EN.html>

Date: October 2019

Pages: 70

Price: US\$ 1,699.00 (Single User License)

ID: SD0B0A15E345EN

## **Abstracts**

Severe Acute Respiratory Syndrome (SARS) Drug pipeline report- 2020 is an annual R&D review of Severe Acute Respiratory Syndrome (SARS) pipeline candidates. The report presents the current status of all major Severe Acute Respiratory Syndrome (SARS) therapeutic compounds. Detailed insights into Severe Acute Respiratory Syndrome (SARS) pipeline development, current status, companies, drug profiles and Severe Acute Respiratory Syndrome (SARS) preclinical and clinical trials are included.

### **2020 Severe Acute Respiratory Syndrome (SARS) Pipeline Market Insights**

Severe Acute Respiratory Syndrome (SARS) disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Severe Acute Respiratory Syndrome (SARS) therapies, pipeline by phase and others are included.

### **Severe Acute Respiratory Syndrome (SARS) pipeline Drug profiles-**

Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

### **Severe Acute Respiratory Syndrome (SARS) Therapeutic Drug candidates**

Both active and inactive Severe Acute Respiratory Syndrome (SARS) pipeline drug candidates are included in the report

### **Severe Acute Respiratory Syndrome (SARS) Clinical Trials and preclinical Studies**

Severe Acute Respiratory Syndrome (SARS) In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Severe Acute Respiratory Syndrome (SARS) pipeline market developments  
Severe Acute Respiratory Syndrome (SARS) Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Severe Acute Respiratory Syndrome (SARS) pipeline companies in active development  
The report analyzes Severe Acute Respiratory Syndrome (SARS) pipeline of the below companies-

Atriva Therapeutics GmbH, Autoimmune Technologies LLC, Biotron Ltd , CEL-SCI Corp, Fab'entech SA, GeneCure LLC, Gilead Sciences Inc, Global BioLife Inc Ltd, MassBiologics, Novavax Inc, Oncovir Inc, Phelix Therapeutics LLC, Sagimet Biosciences

## Report Coverage

### What to look out for in 2020

Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

### Pipeline Snapshot

Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

### Companies

13 Companies investing in Severe Acute Respiratory Syndrome (SARS) pipeline from discovery stage to pre-registration phase are included

### Drug profiles

Over 10 details of each Severe Acute Respiratory Syndrome (SARS) pipeline candidate are included

### Company Profiles

Business overview and contact details of all companies operating in the industry are provided

## Market Developments

News, Developments and other recent industry developments are included

## Contents

### **1. SEVERE ACUTE RESPIRATORY SYNDROME (SARS) PIPELINE MARKET INSIGHTS, 2020**

- 1.1 Severe Acute Respiratory Syndrome (SARS) Disease Overview
- 1.2 Severe Acute Respiratory Syndrome (SARS) Drug Pipeline Snapshot, 2020
  - 1.2.1 Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs by Phase
  - 1.2.2 Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs by Company
  - 1.2.3 Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs by Mechanism of Action
  - 1.2.4 Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs by Route of Administration

### **2. SEVERE ACUTE RESPIRATORY SYNDROME (SARS) COMPANY WISE PIPELINE DETAILS**

- Atriva Therapeutics GmbH Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs
  - Company Profile
  - Drug Candidate Details
- Autoimmune Technologies LLC Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs
  - Company Profile
  - Drug Candidate Details
- Biotron Ltd Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs
  - Company Profile
  - Drug Candidate Details
- CEL-SCI Corp Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs
  - Company Profile
  - Drug Candidate Details
- Fab'entech SA Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs
  - Company Profile
  - Drug Candidate Details
- GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs
  - Company Profile
  - Drug Candidate Details
- Gilead Sciences Inc Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs
  - Company Profile
  - Drug Candidate Details

Global BioLife Inc Ltd Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs

Company Profile

Drug Candidate Details

MassBiologics Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs

Company Profile

Drug Candidate Details

Novavax Inc Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs

Company Profile

Drug Candidate Details

Oncovir Inc Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs

Company Profile

Drug Candidate Details

Phelix Therapeutics LLC Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs

Company Profile

Drug Candidate Details

Sagimet Biosciences Severe Acute Respiratory Syndrome (SARS) Pipeline Drugs

Company Profile

Drug Candidate Details

### **3. SEVERE ACUTE RESPIRATORY SYNDROME (SARS) DRUG PIPELINE PROFILES**

3.1 Discovery and Preclinical Drug Profiles

3.2 Phase 1 Drug Profiles

3.3 Phase 2 Drug Profiles

3.4 Phase 3 Drug Profiles

### **4. SEVERE ACUTE RESPIRATORY SYNDROME (SARS) PIPELINE NEWS AND DEVELOPMENTS**

### **5. APPENDIX**

5.1 Primary and Secondary Research Methodology

5.2 Publisher Expertize

5.3 Contacts

## I would like to order

Product name: Severe Acute Respiratory Syndrome (SARS) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

Product link: <https://marketpublishers.com/r/SD0B0A15E345EN.html>

Price: US\$ 1,699.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SD0B0A15E345EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970